NEW WORK SE | 251.00 / +0.40% |
Date/Time | 01/20 / 10:20 |
Chg. / Chg.(%) | 1.00 / +0.40% |
Bid | - |
Ask | - |
Open | 253.00 |
Previous Close | 250.00 |
High | 253.00 |
Low | 251.00 |
Volume [EUR] | 4,541.00 |
Volume [Units] | 18 |
Price fixings | 4 |
ISIN | DE000NWRK013 |
Security | NWO/D |
Exchange | Turquoise |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Xetra | 251.00 | ![]() |
604 |
TradeGate | 250.50 | ![]() |
62 |
Turquoise | 251.00 | ![]() |
18 |
Cboe Europe .. | 251.00 | ![]() |
18 |
Hannover | 249.00 | ![]() |
3 |
Vienna Globa.. | 249.50 | ![]() |
0 |
Frankfurt | 249.0000 | ![]() |
0 |
Berlin | 249.00 | ![]() |
0 |
Hamburg | 249.00 | ![]() |
0 |
Düsseldorf | 250.00 | ![]() |
0 |
München | 248.50 | ![]() |
0 |
Stuttgart | 250.500 | ![]() |
|
Lang & Schwa.. | 250.00 | ![]() |
|
gettex | 251.000 | ![]() |
|
London Inter.. | 251.50 | 2,659 | |
Cboe Europe .. | 265.00 | 39 | |
Cboe Europe .. | 288.00 | 14 | |
EUREX | Options |
News
- WISeKey’s WISeID Identity Offers a Zero Trust Approach to Secure Remote Work
01/19/2021 / 18:00 - GlobeNewswire - Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies
01/19/2021 / 14:30 - GlobeNewswire - AspireHR Accelerates Adoption of Travel, Expense, and Invoice Solutions in North America with SAP Concur Partnership
01/14/2021 / 16:15 - GlobeNewswire - CamScanner Helps Millions of People Improve Efficiency while Working Remotely
01/14/2021 / 13:00 - GlobeNewswire - 84% of Americans Report that Quarantine Mandates Blur the Lines Between Work and Personal Lives
01/12/2021 / 15:00 - GlobeNewswire